Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Washout (3 weeks) Clear all
Completed Phase 2 Interventional Results available

Treatment for Calcium Phosphate Kidney Stone Disease

NCT01754779
View directory record Official record
Conditions
Calcium Phosphate Kidney Stones
Interventions
Placebo, Citric Acid, Potassium Citrate
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 4 Interventional Results available

Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder

NCT00120250
View directory record Official record
Conditions
Post-Traumatic Stress Disorders
Interventions
Eszopiclone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])

NCT04403399
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
45 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 4, 2026, 10:47 AM EDT
Terminated Not applicable Interventional Results available

Oxytocin Add on Study for Stable Schizophrenic Patients

NCT00506909
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
David Feifel
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 4, 2026, 10:47 AM EDT
Withdrawn Phase 1 Interventional

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

NCT01685489
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, PSK®, Docetaxel, Placebo
Drug
Lead sponsor
Bastyr University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps

NCT04998305
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Muscle Cramp
Interventions
TJ-68, Placebo
Drug
Lead sponsor
Hiroshi Mitsumoto
Other
Eligibility
20 Years to 84 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 4, 2026, 10:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Gene by Medication Interaction to the Acute Effects of Alcohol

NCT01343628
View directory record Official record
Conditions
Alcohol-induced Cue-craving, Alcohol Sensitivity
Interventions
Placebo Comparator, Active Comparator: Atomoxetine, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Charlottesville/ Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Efficacy of Pea Hull Fiber in Chronic Disease

NCT03354364
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
Pea hull fiber, Control
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 4, 2026, 10:47 AM EDT
Completed No phase listed Observational

A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease

NCT01149811
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Fipamezole ODT, Fipamezole ODT Cohort 2
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Torrance, California • Tampa, Florida • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Circadian Rhythms of Aqueous Humor Dynamics in Humans

NCT00572936
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Dorzolamide, Timolol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics

NCT03220776
View directory record Official record
Conditions
Alcohol Use Disorder, Bipolar Disorder
Interventions
N-Acetylcysteine, Gabapentin, Placebo Oral Tablet
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

NCT01027364
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
Factor IX (rFIXFc), rFIX
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 4 Interventional Results available

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

NCT02799784
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, TIO/OLO, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Ultralow Dose PAH Binary Mixture Study

NCT03631667
View directory record Official record
Conditions
Environmental Exposure
Interventions
[14C]-benzo[a]pyrene, [14C]-benzo[a]pyrene plus phenanthrene
Drug
Lead sponsor
Oregon State University
Other
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.

NCT01762475
View directory record Official record
Conditions
Traumatic Brain Injury, Post-concussive Syndrome
Interventions
Sildenafil
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 4, 2026, 10:47 AM EDT
Not listed Phase 2 Interventional

Catamenial Epilepsy Treatment

NCT01299870
View directory record Official record
Conditions
Epilepsy
Interventions
AED treatment plus placebo, Keishibukuryogan
Drug
Lead sponsor
Timothy Welty, PharmD
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 4, 2026, 10:47 AM EDT
Active, not recruiting Phase 2 Interventional

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

NCT03775096
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
Interventions
Carvedilol
Drug
Lead sponsor
Michele Tagliati, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Multimodal Exercises to Improve Leg Function After Spinal Cord Injury

NCT01740128
View directory record Official record
Conditions
Spinal Cord Injuries, Paraplegia, Paraparesis
Interventions
Robotic body weight supported treadmill training, Harness-supported multimodal balance training
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

NCT01194245
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Escondido, California • La Jolla, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 4, 2026, 10:47 AM EDT
Withdrawn Phase 2 Interventional

Dronabinol for Agitation in Dementia Crossover Trial

NCT05612711
View directory record Official record
Conditions
Dementia Moderate, Dementia Severe, Agitation,Psychomotor, Behavioral Symptoms
Interventions
Dronabinol
Drug
Lead sponsor
Ralph H. Johnson VA Medical Center
Federal
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet

NCT03802721
View directory record Official record
Conditions
Environmental Exposure
Interventions
[14C]-benzo[a]pyrene, Brussels sprouts before 50 ng dose, DIM supplement before 50 ng dose
Drug
Lead sponsor
Oregon State University
Other
Eligibility
21 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 4, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional

2-HOBA in Systemic Lupus Erythematosus

NCT07225543
View directory record Official record
Conditions
Systemic Lupus Erthematosus (SLE)
Interventions
2-HOBA acetate (2-Hydroxybenzlamine acetate), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 4, 2026, 10:47 AM EDT
Terminated Phase 3 Interventional Results available

Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

NCT02960217
View directory record Official record
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions
UX007, Placebo
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
6 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Aurora, Colorado • Miami, Florida • Norcross, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 4, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Effect of Fish Oil and Vitamin C on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

NCT01057615
View directory record Official record
Conditions
Asthma
Interventions
Fish Oil, Ascorbic Acid, Fish Oil Placebo, Ascorbic Acid Placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2011 · Synced Oct 4, 2026, 10:47 AM EDT